Please assess the completion status of the following clinical trial:

Trial Title: Attention & Memory Impairments in Menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Women ages 45 to 60 will be eligible for this study if they:~* Are within 5 years of their last menstrual period;~* Are able to give written informed consent;~* Must have clear urine toxicology screen upon recruitment;~* Are fluent in written and spoken English;~* Must have negative urine pregnancy test if still menstruating.~Exclusion Criteria:~* History of seizures;~* History of cardiac disease including known cardiac defect or conduction abnormality;~* Abnormal electrocardiogram during screening;~* Use of estrogen therapy within previous 6 months;~* Current pregnancy or planning to become pregnant.~* Presence of a contraindication to treatment with stimulant medication; this would include the presence of hypertension, coronary disease, atrial fibrillation, and arrhythmia.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Lisdexamfetamine, then placebo (Type: EXPERIMENTAL): Participants first received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks followed by a 2-week washout, then they received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks.
- Placebo, then Lisdexamfetamine (Type: EXPERIMENTAL): Participants first received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks followed by a 2-week washout, then they received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).